BB Biotech Adds LB Pharmaceuticals to Investment Portfolio
BB Biotech has initiated a new investment position in clinical-stage biopharmaceutical company LB Pharmaceuticals as part of its portfolio strategy.
Stocks · News reference
LB Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2026
LB Pharmaceuticals announced its financial results for the third quarter of 2026, reporting a net loss of $59.1 million and a cash position of $403.8 million.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Inc announced equity awards to newly appointed Chief Medical Officer Dr. Susan G. Kozauer and Chief Financial Officer Joseph Miller. Each executive received options to purchase 200,000 shares at an exercise price of $37.22, vesting over 4 years with a 10-year term. The grants were made as inducement awards under Nasdaq Listing Rule 5635(c)(4).
LB Pharmaceuticals shares are trading higher after Canaccord Genuity initiated its coverage on the stock with a Buy rating and announced a price target of $65.
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $65.
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80
Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $80.